ChemicalBook > Product Catalog >Pharmaceutical intermediates >Bulk Drug Intermediates >(1R,2S)-2-(3,4-Difluorophenyl)cyclopropanamine (2R)-Hydroxy(phenyl)ethanoate

(1R,2S)-2-(3,4-Difluorophenyl)cyclopropanamine (2R)-Hydroxy(phenyl)ethanoate

(1R,2S)-2-(3,4-Difluorophenyl)cyclopropanamine (2R)-Hydroxy(phenyl)ethanoate Structure
CAS No.
376608-71-8
Chemical Name:
(1R,2S)-2-(3,4-Difluorophenyl)cyclopropanamine (2R)-Hydroxy(phenyl)ethanoate
Synonyms
(1R,2S)-2-(3,4-difluorophenyl)cyclopropan-1-amine;(1R,2S)-2-(3,4-difluorophenyl)cyclopropanaMine (R)-2-hydroxy-2-phenylacetate;(1R,2S)-2-(3,4-Difluorophenyl)cyclopropanaminium (2R)-hydroxy(phenyl)ethanoate;(1R,2S)-2-(3,4-difluorophenyl)cyclopropan-1-amine (R)-2-hydroxy-2-phenylacetate;(1R,2R)-2-(3,4-difluorophenyl)cyclopropanamine(S)-(carboxylato(phenyl)methyl)holmium;(1R 2S)-2-(3 4- DIFLUOROPHENYL) CYCLOP ROPANAMINIUM (2R)- HYDROXY(PHENYL) ETHAN OATE MANDELIC ACID SALT;EX-7182;2S)-2-(3;Ticagrelor int4;)ethanoate, 98%
CBNumber:
CB62535571
Molecular Formula:
C17H17F2NO3
Molecular Weight:
321.32
MOL File:
376608-71-8.mol
MSDS File:
SDS
Modify Date:
2024/4/16 14:59:45

(1R,2S)-2-(3,4-Difluorophenyl)cyclopropanamine (2R)-Hydroxy(phenyl)ethanoate Properties

Melting point 161 °C
storage temp. under inert gas (nitrogen or Argon) at 2–8 °C
solubility DMSO (Slightly), Methanol (Slightly)
form Solid
color White to Off-White
Major Application Pharmaceutical intermediates
InChI InChI=1/C9H9F2N.C8H8O3/c10-7-2-1-5(3-8(7)11)6-4-9(6)12;9-7(8(10)11)6-4-2-1-3-5-6/h1-3,6,9H,4,12H2;1-5,7,9H,(H,10,11)/t6-,9+;7-/s3
InChIKey GUESUQPLVFMJIT-RUKVIUEPNA-N
SMILES [C@H](C1C=CC=CC=1)(O)C(=O)O.N[C@@H]1C[C@H]1C1C=CC(F)=C(F)C=1 |&1:0,12,14,r|

SAFETY

Risk and Safety Statements

Symbol(GHS) 
GHS07
Signal word  Warning
Hazard statements  H302-H315-H319-H335
Precautionary statements  P261-P305+P351+P338
Safety Statements  24/25
HS Code  29181990

(1R,2S)-2-(3,4-Difluorophenyl)cyclopropanamine (2R)-Hydroxy(phenyl)ethanoate Chemical Properties,Uses,Production

Description

(1R, 2R)-2-(3, 4-difluorophenyl) cyclopropanamine(S)-(carboxylato(phenyl)methyl) holmium is a useful pharmacological intermediate. It is utilized as an intermediate of trcagrelor, which is a platelet aggregation inhibitor used for prevention of thrombotic events occurring in people with acute coronary syndrome or myocardial infarction.

Chemical Properties

White to off-white powder

Uses

(1R,2S)-2-(3,4-Difluorophenyl)cyclopropanamine is an intermediate in the preparation of orally active reversible P2Y12 receptor antagonists for the prevention of thrombosis.

Synthesis

1. Trans-(1R,2S)-2-(3,4-difluorophenyl)-1-nitro cyclopropane (215.0 g) was added to the pre-cooled methanolic hydrochloric acid (6.0% to 7% w/w HCl, 4300 ml), followed by cooling the mass to -5 to 0° C. Zinc dust (343.71 g) was added to the resulting mass over a period of 2 to 3 hours while maintaining the temperature at -5 to 0° C. The reaction mass was stirred further for 2 hours at -5 to 0° C. After completion of the reaction, the reaction mass was filtered through a hyflo bed and the bed was washed with methanol (2×215 ml). The main filtrate and washings were combined, followed by distillation under reduced pressure.
2. The resulting residue was dissolved in dichloromethane (1075 ml) and then cooled to 10 to 15° C. 25% Aqueous ammonia solution (1290 ml) was added to the cooled solution while maintaining the temperature at below 30° C. The resulting reaction mass was stirred for 15 minutes, followed the by layer separation. The resulting aqueous layer was extracted with dichloromethane (2×537.5 ml) and then combined with the main dichloromethane layer. The combined dichloromethane layer containing the product was extracted thrice with aqueous hydrochloric acid (645 ml of conc. hydrochloric acid mixed with 1935 ml water, 3×865 ml). The aqueous acidic layer containing the product was combined and washed with dichloromethane (645 ml). Dichloromethane (1075 ml) was added to the acidic aqueous layer, followed by the addition of 25% aqueous ammonia solution (1505 ml) while maintaining the temperature at below 30° C. The resulting reaction mass was extracted with dichloromethane (2×645 ml) and then combined with the main dichloromethane layer. The combined dichloromethane layer containing the product was washed with water (645 ml) and evaporated to dryness under reduced pressure.
3. The resulting residue was dissolved in methanol (430 ml), followed slow addition of (R)-(-)-mandelic acid solution (107.5 g in 645 ml methanol) over a period of 40 to 60 minutes while maintaining temperature at 20 to 25° C. The resulting slurry was stirred further for 12 hours at 20 to 25° C., followed by further cooling to 0 to 5° C. The cooled solution was stirred for 2 hours and the solid was isolated by filtration. The resulting solid was washed with chilled methanol (215 ml). The solid was dried under reduced pressure at 40 to 45° C. to obtain 127 g of pure (1R,2S)-2-(3,4-Difluorophenyl)cyclopropanamine (2R)-Hydroxy(phenyl)ethanoate as a white solid.

References

http://www.tradekorea.com/product/detail/P483269/Ticagrelor-intermediates---CAS-376608-71-8.html
https://en.wikipedia.org/wiki/Ticagrelor

(1R,2S)-2-(3,4-Difluorophenyl)cyclopropanamine (2R)-Hydroxy(phenyl)ethanoate Preparation Products And Raw materials

Global( 430)Suppliers
Supplier Tel Country ProdList Advantage Inquiry
Bulat Pharmaceutical Pvt Ltd +91-8448085659 +91-8448085660 Haryana, India 123 58 Inquiry
Vidgas science and technologies Pvt Ltd +91-9030019844 +91-9030019844 Telangana, India 76 58 Inquiry
Neugen Labs +91-8133254502 +91-8133254502 Karnataka, India 195 58 Inquiry
Chempifine Chemicals +91-2225667766 +91-2225667766 Punjab, India 144 58 Inquiry
Trignokem International +91 (40) 2717-0709 New Delhi, India 380 50 Inquiry
CLEARSYNTH LABS LTD. +91-22-45045900 Hyderabad, India 6351 58 Inquiry
A.J Chemicals 91-9810153283 New Delhi, India 6124 58 Inquiry
Solgeniz Industries 08069023792Ext 260 Pune, India 46 58 Inquiry
A. B. Enterprises +91-8048077585 Mumbai, India 1396 58 Inquiry
Peritum Innovations Llp 08048973761 Gujarat, India 17 58 Inquiry

(1R,2S)-2-(3,4-Difluorophenyl)cyclopropanamine (2R)-Hydroxy(phenyl)ethanoate Spectrum

(1R,2S)-2-(3,4-Difluorophenyl)cyclopropanaMine (2R)-Hydroxy(phenyl)ethanoate (αR)-α-Hydroxybenzeneacetic Acid coMpd. with (1R,2S)-2-(3,4-Difluorophenyl)cyclopropanaMine trans-(1R,2S)-2-(2,3-difluorophenyl)cyclopropylaMine Mandelat (alphaR)-alpha-Hydroxybenzeneacetic acid compd. with (1R,2S)-2-(3,4-difluorophenyl)cyclopropanamine (αR)-(1R,2S)-α-hydroxy-Benzeneacetic acid-coMpd.with 2-(3,4-difluorophenyl)cyclopropanaMine(1:1) Ticagrelor InterMediate 4 (1R,2S)-2-(3,4-Difluorophenyl) cyclopropylamine D-Mandelate (1R,2S)-2-(3,4-Difluorophenyl)cyclopropanaminium (1R,2S)-2-(3,4-Difluorophenyl)cyclopropanamine (2R)-Hydroxy(phenyl)ethanoate Ticagrelor Intermediate3 (1S,2R)-2-(3,4-difluorophenyl)cyclopropan-1-amine (R)-2-hydroxy-2-phenylacetate Benzeneacetic acid, α-hydroxy-, (αR)-(1R,2S)-coMpd. with 2-(3,4-difluorophenyl)cyclopropanaMine (1:1) (1R,2S)-2-(3,4-difluorophenyl)cyclopropanaMine (R)-2-hydroxy-2-phenylacetate(1:1) (1R,2S)-2-(3,4-difluorophenyl)cyclopropanaMine with (R)-(-)-Mandelic acid (1:1) Benzeneaceticacid,a-hydroxy-,(R)-(1R,2S)-coMpd.with2-(3,4-difluorophenyl)cyclopropanaMine(1:1) (1R,2S)-2-(3,4-Difluorophenyl)cyclopropanaMiniuM(2R)-hydroxy(phenyl) (1R,2S)-2-(3,4-Difluorophenyl)cyclopropanaMiniuM (2 (1R,2S)-2-(3,4-difluorophenyl)cyclopropanaMine (S)-2-hydroxy-2-phenylacetate (1R,2S)-2-(3,4-dimethylphenyl)cyclopropanamine (R)-2-hydroxy-2-phenylacetate (1R,2S)-2-(3,4-Difluorophenyl) cyclopropanaminium (2R)-hydroxy(phenyl)ethanoat Trans-(1R,2S)-2-(3,4-difluorophenyl)cyclopropylamine mandelate (1R,2S)-2-(3,4-Difluorophenyl)cyclopropanamine (R)-2-hydroxy-2-phenylacetic acid (1S,2R)-2-(3,4- difluorophenyl)cyclopropan-1-amine hydrochloride EX-7182 (1R-2R)-2-(3,4-diflrorophenyl)cyclopropanamine (aR)-a-Hydroxy-benzeneacetic acid compd. with (1R,2S)-2-(3,4-difluorophenyl) cyclopropanamine (1:1) (1R,2S)-2-(3,4-Difluorophenyl)cyclopropanamine (2R)-Hydroxy(phenyl)ethanoate 376608-71-8 (1R 2S)-2-(3 4-DIFUOROPHENYL)CYCLOPROPAN AMINIUM(2R)-HYDROXY(PHENYL)ETHANOATE Ticagrelor int4 (1R,2S)-2-(3,4-Difluorophenyl)cyclopropan-1-ammonium (2R)-2-hydroxy-2-phenylacetate (1R,2S)-2-(3,4-Difluorophenyl)cyclopropanaMine (2R)-Hydroxy(phenyl)etha (1R,2S)-2-(3,4-Difluorophenyl)-cyclopropan-1-amine (2R)-2-hydroxy-2-phenylacetic acid trans-(1R,2S)-2-(3,4-Difluorophenyl)cyclopropanaminium (2R)-2-hydroxy-2-phenylethanoate (1R,2S)-2-(3,4-DifL )ethanoate, 98% opropanaminium (2R)-hydroxy(phenyL Ticagrelor Related Compound 107 (1R,2S)-2-(3,4-Difluorophenyl)cyclopropanamine (2R)-Hydroxy(phenyl)ethanoate ISO 9001:2015 REACH 1-Acetyladamantane Intermediate,(1R,2S)-2-(3,4- Difluorophenyl)cyclopropanamine (2R)-Hydroxy(phenyl)ethanoate 2S)-2-(3 4-Difluorophenyl)cyclopropanamine (2R)-Hydroxy(phenyl)ethanoate Ticagrelor side chain 2 mandelate carboxylato(phenyl) methyl)holmium trans-(1R,2S)-2-(3,4-difluorophenyl)cyclopropanamine (2R)-2-hydroxy-2-phenylethanoate (1R,2S)-2-(3,4-DIFLUOROPHENYL)CYCLOPROPANAMINE (2R) -2-HYDROXY-2-PHENYLACETATE (1R,2R)-2-(3,4-difluorophenyl) cyclopropanamine(S)-(carboxyl... Ticagrelor EP Impurity B (1R,2R)-2-(3,4-difluorophenyl)cyclopropanamine(S)-(carboxylato(phenyl)methyl)holmium (1R,2S)-2-(3,4-Difluorophenyl)cyclopropanaminium (2R)-hydroxy(phenyl)ethanoate (1R,2S)-2-(3,4-difluorophenyl)cyclopropan-1-amine (1R,2S)-2-(3,4-difluorophenyl)cyclopropanaMine (R)-2-hydroxy-2-phenylacetate (1R,2S)-2-(3,4-difluorophenyl)cyclopropan-1-amine (R)-2-hydroxy-2-phenylacetate (1R 2S)-2-(3 4- DIFLUOROPHENYL) CYCLOP ROPANAMINIUM (2R)- HYDROXY(PHENYL) ETHAN OATE MANDELIC ACID SALT (1R,2S)-2-(3,4-difluorophenyl)cyclopropanamine D-Mandelic acid Benzeneacetic acid, α-hydroxy-, (αR)-(1R,2S)-compd. with 2-(3,4-difluorophenyl)cyclopropanamine (1:1) (1R,2S)-2-(3,4-Difluorophenyl)cyclopropanamine (2R)-Hydroxy(phenyl)ethanoate(1R,2S)-2-(3,4-Difluorophenyl)cyclopropanamine (2R)-Hydroxy(phenyl)ethanoate Ticagrelor EP Impurity E (R)-Mandelate (1R,2S)-2-(3,4-Difluorophenyl)cyclopropanaminium (2R)-hydroxy(phenyl)ethanoate (Ticagrelor Impurity)